ATE377760T1 - Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen - Google Patents

Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen

Info

Publication number
ATE377760T1
ATE377760T1 AT02781372T AT02781372T ATE377760T1 AT E377760 T1 ATE377760 T1 AT E377760T1 AT 02781372 T AT02781372 T AT 02781372T AT 02781372 T AT02781372 T AT 02781372T AT E377760 T1 ATE377760 T1 AT E377760T1
Authority
AT
Austria
Prior art keywords
cardiovascular diseases
concentration
reducing
methods
relates
Prior art date
Application number
AT02781372T
Other languages
English (en)
Inventor
Jamila Najib
Zouher Majd
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Application granted granted Critical
Publication of ATE377760T1 publication Critical patent/ATE377760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
AT02781372T 2001-09-07 2002-09-06 Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen ATE377760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0111598A FR2829581A1 (fr) 2001-09-07 2001-09-07 Methodes de criblage de molecules utiles pour la prevention ou le traitement du syndrome metabolique, des maladies cardiovasculaires et de l'atherosclerose

Publications (1)

Publication Number Publication Date
ATE377760T1 true ATE377760T1 (de) 2007-11-15

Family

ID=8867065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02781372T ATE377760T1 (de) 2001-09-07 2002-09-06 Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen

Country Status (9)

Country Link
US (1) US20040198656A1 (de)
EP (1) EP1423707B1 (de)
JP (1) JP2005502883A (de)
AT (1) ATE377760T1 (de)
CA (1) CA2459945A1 (de)
DE (1) DE60223390D1 (de)
FR (1) FR2829581A1 (de)
IL (1) IL160533A0 (de)
WO (1) WO2003023407A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604333A1 (en) * 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
JP5373322B2 (ja) * 2007-06-05 2013-12-18 株式会社バイオマーカーサイエンス 動脈硬化改善・予防効果の評価方法、物質のスクリーニング方法、並びに、マーカーとしての使用
WO2009148050A1 (ja) * 2008-06-04 2009-12-10 株式会社バイオマーカーサイエンス 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
AU2019207737B2 (en) 2018-01-10 2023-07-13 Brightseed, Inc. Method for modulating metabolism
KR102892573B1 (ko) 2019-07-29 2025-12-01 브라이트씨드, 인크. 소화기 건강의 개선 방법
JP2023501483A (ja) 2019-11-11 2023-01-18 ブライトシード・インコーポレイテッド 抽出物、消費可能な製品及び抽出物における生物活性代謝産物を濃縮するための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
EP0976824A1 (de) * 1998-07-10 2000-02-02 Amsterdam Molecular Therapeutics An der Leberregenration beteiligtes Gen und Protein
EP1144444A3 (de) * 1998-12-22 2002-01-02 Genset Kodierende nuleinsäuren für proteine mit signalsequenzen
US20030032783A1 (en) * 1998-12-22 2003-02-13 Frances Yen-Potin Apolipoprotein A-IV-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof
WO2001000661A2 (en) * 1999-06-25 2001-01-04 Genset Carnitine carrier related protein-1
EP1276754A4 (de) * 2000-04-14 2005-04-06 Nuvelo Inc Materialien und verfahren betreffend den lipidmetabolismus

Also Published As

Publication number Publication date
CA2459945A1 (fr) 2003-03-20
DE60223390D1 (de) 2007-12-20
WO2003023407A1 (fr) 2003-03-20
EP1423707A1 (de) 2004-06-02
JP2005502883A (ja) 2005-01-27
US20040198656A1 (en) 2004-10-07
IL160533A0 (en) 2004-07-25
EP1423707B1 (de) 2007-11-07
FR2829581A1 (fr) 2003-03-14

Similar Documents

Publication Publication Date Title
ATE377760T1 (de) Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen
EP1585482A4 (de) Neue zusammensetzungen und verfahren zur behandlung von psoriasis
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
EE05485B1 (et) Plasmi(i)n(ogeen)i eemaldamine valgulahustest
ATE480643T1 (de) Homogener nachweis von analyten
NO20052928L (no) Nye kjemiske forbindelser
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
ATE456673T1 (de) Verfahren und zusammensetzungen zur messung von natriuretischen peptiden und verwendung dafür
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE498676T1 (de) Produkte auf basis von ionischen flüssigkeiten und verfahren zu deren verwendung
DE60313283D1 (de) Verfahren zur zusammenfassung von unbekanntem videoinhalt
ATE481969T1 (de) Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
DE60326012D1 (de) Verfahren zur Konzentration von Proteinen
ATE381552T1 (de) Derivate von 1-piperazin- und 1- homopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms
EE200300487A (et) Peptiid-põhine immunoteraapia ateroskleroosi raviks ja peptiid-põhise määramise arendamine immuunvastuste määramiseks oksüdeeritud madala tihedusega lipoproteiini vastu
HUP0100668A2 (hu) Virulenciával kapcsolatos nukleinsavszekvenciák és alkalmazásuk
NO20053185L (no) Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.
DE60325946D1 (de) Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
DE60321355D1 (de) Verfahren zur reproduzierung von pleuromutilinen
DE60129015D1 (de) Verfahren zur erkennung von entzündungen und entzündungsbedingungen
NO20051169L (no) Fremgangsmate for a isolere et intestinalt kolesterolbindende protein
ATE333887T1 (de) Verfahren zur behandlung von instabiler angina pectoris
NO20081794L (no) Fremgangsmate for kvantitativ bestemmelse av poloxamere

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties